Abstract. The present study was conducted to investigate the expression of miR-603 in osteosarcoma cells, and the effect of miR-603 on the biological behavior and expression of breast cancer cell 2 (BRCC2) in osteosarcoma cells. In the present study, qRT-PCR was used to measure the levels of miRNA and mRNA. The results showed that miR-603 was significantly upregulated in human osteosarcoma tissues and cell lines. MTT and colony formation assays were employed to evaluate the role of miR-603 in the regulation of osteosarcoma cell proliferation. The results showed that overexpression of miR-603 promoted the proliferation of MG-63 and U2OS cells. Furthermore, a nude mouse subcutaneous tumor model indicated that miR-603 promoted osteosarcoma growth in vivo. Moreover, miR-603 expression levels were increased in patients with distant metastasis in comparison with levels in patients without distant metastasis. We discovered that BRCC2 may be a target of miR-603. Our results demonstrated that overexpression of miR-603 suppressed BRCC2 protein expression, and an miR-603 inhibitor enhanced BRCC2 protein expression as determined by western blot assay and immunohistochemical analysis. Luciferase reporter assays confirmed that BRCC2 is a direct target of miR-603 in osteosarcoma cells, and the results suggest that miR-603 downregulates BRCC2 expression in osteosarcoma via translational inhibition. Finally, we found that the reduction in BRCC2 expression induced by miR-603 was responsible for the enhanced colony formation and proliferative ability noted in the MG-63 and U2OS cells. In conclusion, miR-603 enhanced osteosarcoma growth by downregulation of BRCC2 expression via translational inhibition.
Introduction
Osteosarcoma is a primary mesenchymal tumor characterized histologically by malignant tumor cells that directly produce osteoid or immature bone. It is the most commonly diagnosed primary malignancy of the bone, particularly among children and adolescents (1) . As the disease results in active bone growth and repair (2) , it is highly destructive and metastatic. In the last several decades, therapies utilizing surgery and chemical agents have improved the 5-year survival rate of these patients to ~80% (3) . However, the cure rate of patients bearing osteosarcoma is still very poor, and the majority eventually die of metastases (4) . Thus, an understanding of the genes and molecules involved in osteosarcoma is particularly critical for developing new therapies and improving patient outcomes.
miR-603 has been reported as a tumor suppressor in thyroid cell tumors (5) , laryngeal squamous cell carcinoma (6) and GH adenoma (7) . miR-603 has also been previously reported to be overexpressed in pancreatic (8) , ovarian (9) and colorectal cancer (10) . However, its function in osteosarcoma is not yet known.
Breast cancer cell 2 (BRCC2) is unique among the protooncogenes, being localized to mitochondria and extending cell survival by blocking programmed cell death (11) . BRCC2 expression is reported to prevent apoptosis in a wide variety of cell types, including T-lymphocytes, prostate cancer cells and embryonic sensory neurons (12) . Previous studies have reported that expression of BRCC2 suppresses cellular proliferation and is associated with less aggressive biological behavior and better prognosis (13, 14) .
In the present study, we found that miR-603 is overexpressed in osteosarcoma, as compared to normal non-cancer tissue and a normal human osteoblastic cell line. miR-603 significantly promoted osteosarcoma cell growth in vitro and in vivo. We further demonstrated that BRCC2 is a direct target of miR-603. miR-603 appears to be a potential therapeutic target for use in osteosarcoma treatment.
Materials and methods
Ethical approval. All procedures performed in the studies involving human participants were in accordance with the RNA extraction and quantitative real-time PCR. Total RNAs were extracted from the cultured human tissue specimens and cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. For the detection of mature miR-603 and relative mRNA, RNA was reverse transcribed using a TaqMan reverse transcription kit (Applied Biosystems, Foster City, CA, USA). The reaction was incubated at 94˚C for 4 min followed by 35 cycles of 20 sec at 94˚C, 30 sec at 60˚C and 30 sec at 72˚C. All PCRs were carried out in triplicate on an ABI 7500 Real-Time PCR system (Applied Biosystems), and miRNA and mRNA expression was normalized to U6 snRNA and GAPDH, respectively, using the 2 -ΔΔCt method, and at least 3 independent experiments were performed to generate each data set.
Tumor formation in nude mice. Nude mice (4-weeks old, 18.0-22.0 g in weight) were subcutaneously injected with 2x10 6 cells transfected with either miR-603 mimics or its inhibitor. Every 2 days post-inoculation, the length and width of the implanted tumors were measured with a Vernier caliper. After 3 weeks, the mice were sacrificed to measure tumor weights. The mice were manipulated and housed according to protocols approved by the Local Medical Experimental Animal Care Commission.
Transfection. miRNA-603 mimics and its inhibitor were purchased from GenePharma Co. Ltd. (Shanghai, China). For transfection, MG-63 and U2OS cells were grown to 90% confluency, and transfected with miR-603 mimics or its inhibitor using Lipofectamine 2000 (Invitrogen) by incubation in Opti-Mem I media for 4 h according to the manufacturer's protocols. Cells were harvested 48 or 72 h post-transfection.
The transfection efficiency was confirmed by quantitative real-time PCR analysis. For detecting BRCC2, the cells were transfected again with BRCC2 or its silence gene.
Luciferase reporter assays. Cells cultured into 6-well plates were transfected with 0.05 µg of the pRL-TK vector (Promega, Madison, WI, USA) containing Renilla luciferase along with 30 nM miR-603 mimics or inhibitor. Cells cultured for 24 h were then transfected with BRCC2-wild-type (WT) or BRCC2-mutant reporter plasmid containing firefly luciferase using Lipofectamine 2000. Luciferase activity was measured using a dual luciferase assay system (Promega) 48 h posttransfection. Renilla activity was normalized to firefly activity to control for transfection efficiency.
MTT assay. The transfected cells were seeded into 96-well plates at a density of 3x10 3 cells/well. MTT solution (20 µl of 5 mg/ml MTT) was added to each well (for a total volume of 250 µl), and the plates were incubated for 4 h at 37˚C. Following the removal of the culture medium, the remaining crystals were dissolved in dimethylsulfoxide (DMSO), and the absorbance was measured at 570 nm using a microplate reader. Cell proliferation was assessed daily for 4 consecutive days.
Colony formation assay. Different cells were seeded in triplicate at 500 cells/6-cm dishes in complete medium. The cells were then cultured in DMEM containing 10% FBS and DMEM was changed every 2 days. After incubation for 15 days, the cells were fixed with methanol and stained with 0.1% crystal violet. Visible colonies were manually counted. Triplicate wells were measured for each group.
Immunohistochemistry. All steps were carried out at room temperature as previously described (15) . Cells transfected with miR-603 mimics or its inhibitor were plated on poly-Dlysine-coated glass coverslips 72 h post-transfection and were fixed in 4% (w/v) paraformaldehyde (Electron Microscopy Sciences) for 1 h, washed in phosphate-buffered saline (PBS) (Invitrogen) (6 times, 5 min each), incubated for 1 h in blocking buffer (PBS, 0.8% Triton X-100, 10% normal goat serum), and then incubated overnight in blocking buffer with anti-BRCC2 (1:100) antibodies. The cells were washed in PBS (6 times, 5 min each) before the addition of goat anti-mouse secondary antibodies (Invitrogen, Molecular Probes) at 1:250 for 60 min followed by washing in PBS (6 times, 5 min each). Finally, the slides were incubated with 3,3'-diaminobenzidine (BioGenex Laboratories, San Ramon, CA, USA) and color development was closely monitored under a microscope. The slides were counterstained with hematoxylin.
Western blotting. Western blotting was used to detect the expression of BRCC2 at the protein level as previously described (15) . Anti-β-actin (Abcam) was used as the protein-loading control. The protein complex was detected with enhanced chemiluminescence reagents. Digital images were visualized using the electrochemiluminescence detection system (Invitrogen).
RNA interference for BRCC2. One siRNA lentivirus against BRCC2 and a non-targeting siRNA (both from Sigma-Aldrich) were transfected into U2OS-anti-miR-603 cells in 48-well plates according to the manufacturer's instructions. The multiplicity of infection (MOI; number of transducing lentiviral particles/cell) was 5. Puromycin selection was performed at a concentration of 0.5 µg/ml for 10 days.
Statistical analysis. All data are presented as the mean ± standard error of the mean (SEM). Statistical significance was determined using t-test or analysis of variance (ANOVA) using the SPSS 18.0 program. p<0.05 was considered to indicate a statistically significant difference.
Results

miR-603 is upregulated in human osteosarcoma carcinoma tissues and cell lines.
To explore the expression level of miR-603 in human osteosarcoma carcinoma development, miR-603 expression was assessed in 50 paired osteosarcoma carcinoma and adjacent non-tumor tissues. According to the qRT-PCR analysis, miR-603 was strongly upregulated in the 50 tumor tissues by 1.5-to 6-fold when compared with that in the matched non-tumor tissues (Fig. 1A and B) . We next examined miR-6-3 expression levels in a panel of 4 widely used human osteosarcoma cell lines in comparison to levels in the non-malignant cell line hFOB 1.19. Correspondingly, miR-603 expression levels were consistently increased in the osteosarcoma cell lines (Fig. 1C) . To investigate the clinical impact of elevated miR-603 expression in osteosarcoma, we assessed the association between miR-603 expression levels and clinical outcome. miR-603 expression levels were statistically increased in patients of stage III-IV in comparison to the stage I-II (Fig. 1D) . Furthermore, in order to determine the prognostic impact of miR-603 expression in osteosarcoma, we categorized osteosarcoma patients into two groups based on miR-603 expression levels. Patients with tumors displaying high miR-603 expression levels had a significantly reduced rate of survival compared to those with low miR-603 (Fig. 2) .
Overexpression of miR-603 in MG-63 cells enhances tumorigenesis in vitro and in vivo.
To evaluate a possible involvement of miR-603 in osteosarcoma tumorigenesis, we examined its expression level in human osteosarcoma. We established MG-63 cells overexpressing miR-603 by introducing miR-603 mimics using lentiviral vectors. The miR-603 expression levels were tested using qRT-PCR, and the results showed that the miR-603 group expressed higher miR-603 levels as compared with the vector group (Fig. 3A) . We next tested the hypothesis that overexpression of miR-603 in MG-63 cells promotes cell growth and colony formation ability. We performed MTT and colony formation assays. The MTT assay showed that high expression of miR-603 resulted in more rapid proliferation compared with the vector group (Fig. 3B) . Furthermore, transfection with miR-603 mimics resulted in significantly promoted colony formation under serum starvation (Fig. 3C) . The two results indicated that miR-603 is potentially oncogenic. The miR-603-mediated tumorigenic effects were confirmed in a nude mouse subcutaneous tumor model. The results demonstrated that cells in the miR-603 group formed progressively growing solid tumors. By contrast, cells in the vector group produced much smaller tumors (Fig. 4A) . Finally, as shown in Fig. 4A and B, overexpression of miR-603 promoted tumor growth in vivo. All of these findings above demonstrated that miR-603 induces a more aggressive phenotype of osteosarcoma carcinoma.
Inhibition of miR-603 in U2OS cells reduces tumorigenesis in vitro and in vivo.
We suppressed miR-603 expression in U2OS cells by introducing anti-miR-603 mimics using lentiviral vectors. The suppression of miR-603 expression was confirmed using qRT-PCR (Fig. 5A ). To corroborate this hypothesis, we investigated whether downregulation of miR-603 in U2OS cells reduces cell growth and colony formation ability. MTT and colony formation assays were also carried out. The proliferation curve showed that cells in the anti-miR-603 group exhibited significant decline in proliferation when compared to cells in the vector group (Fig. 5B) . Furthermore, transfection with anti-miR-603 mimics obviously restrained colony formation under serum starvation (Fig. 5C ). Animal studies were conducted to further evaluate the effect of anti-miR-603 on osteosarcoma tumor growth in a nude mouse subcutaneous tumor model. The results demonstrated that cells in the vector group formed progressively growing solid tumors. By contrast, in the anti-miR-603 group much smaller tumors were formed (Fig. 6A) . Finally, the mean weight of tumors in the control group was significantly higher than that in the anti-miR-603 group (Fig. 6B) .
miR-603 reduces the protein levels of BRCC2 by inhibiting translation.
In order to explore the mechanisms by which miR-603 promotes osteosarcoma tumorigenesis, in silico prediction models were employed to search for genes regulated by miR-603. We chose to investigate signal transducer and activator of BRCC2 as a possible target of miR-603 since it is a known tumor-suppressor gene that has been previously reported to be a direct target of miR-603. To confirm that BRCC2 is a target of miR-603, the RNA levels of BRCC2 were assessed in MG-63 cells overexpressing miR-603 (Fig. 7C ) and U2OS cells with silenced miR-603 (Fig. 7D) . Correlation between miR-603 and BRCC2 expression was assessed by western blot analysis (Fig. 8A ) and the immunohistochemical analysis in vivo (Fig. 8B and C) . We found that BRCC2 was downregulated in the miR-603-overexpressing cells, whereas BRCC2 was increased by the miR-603-specific inhibitor compared with that observed in the vector cells. We also repeated the luciferase assay to confirm BRCC2 as a target of miR-603 in osteosarcoma cells, and assessed whether miR-603 inhibits the translation of BRCC2. One potential binding site for miR-603 was located on the 3'-UTR of BRCC2 mRNA ( Fig. 7A and B) . To further validate whether a miR-603 binding site in the BRCC2 3'-UTR mediated this suppression, we inserted the BRCC2 3'-UTR transcript or a mutated version into the luciferase system. The detection of luciferase activity showed that the activity of luciferase combined with wild-type BRCC2 3'-UTR was decreased in the MG-63-miR-603 cells and increased in the U2OS-anti-miR-603 cells, whereas the luciferase activity was not altered by the vector when BRCC2 3'-UTR possessing a mutation in the putative miR-603 binding site. As no significant differences in the BRCC2 mRNA levels were observed between the MG-63 vector as well as U2OS controls, miR-603 did not appear to degrade BRCC2 mRNA ( Fig. 7C and D) . These results together suggest that miR-603 downregulates BRCC2 expression in osteosarcoma via translational inhibition.
BRCC2 is responsible for the colony-forming and proliferative ability of MG-63 and U2OS cells.
In order to investigate the correlation between BRCC2 expression and colony-forming and proliferativen ability of the osteosarcoma cells, we constructed MG-63-miR-603 cells transfected with BRCC2 and U2OS-anti-miR-603 cells transfected with specific siRNAs against BRCC2. The expression of BRCC2 at the protein level was analyzed by western blotting. The results confirmed that BRCC2 expression was significantly upregulated in the MG-63-miR-603 cells (Fig. 9A) and silenced in U2OS-anti-miR-603 cells (Fig. 10A) . Then, the treated cells were evaluated for tumorigenesis using MTT and colony formation assays. As expected, overexpression of BRCC2 strongly suppressed cell proliferation compared to the vector cells (Fig. 9B ) and clearly decreased colony formation ability (Fig. 9C) . Inhibition of BRCC2 expression strongly promoted cell proliferation compared to the control cells (Fig. 10B ) and increased colony formation (Fig. 10C) . Collectively, these results indicate that reduced BRCC2 expression induced by miR-603 is responsible for colony-forming and proliferation ability of the MG-63 and U2OS cells.
Discussion
miRNAs are a type of small-molecule non-coding RNAs, which play an important role in the regulation of post-transcriptional gene expression levels. The functions of miRNAs vary in various clinical diseases and may regulate all aspects of bioactivities, including differentiation and development, metabolism, proliferation, apoptotic cell death, viral infection and tumorigenesis (16) . Abnormal cellular development, as occurs in cancer, has also been associated with miRNAs (17) . The miRNAs with increased expression levels in tumors may function as oncogenes by negatively regulating tumorsuppressor genes. In contrast, the miRNAs downregulated in cancer may function as tumor suppressors and inhibit cancer development by downregulating responding oncogenes (18).
To summarize, miRNAs participate in all stages of tumor development. Osteosarcoma is one of the most common tumors that threats human life. The incidence of osteosarcoma accounts for 20% of all primary malignant bone tumors, behind multiple myeloma. Typical osteosarcoma is a highly malignant intramedullary tumor, accounting for 85% of all bone sarcoma (19) . Study of the relationships between miRNAs and osteosarcoma may provide a new direction for the diagnosis and treatment of osteosarcoma. In previous studies, miR-143, miR-145, miR-195, miR-133a, miR-218 and miR-34a were reported to inhibit osteosarcoma cell proliferation and to suppress tumorigenicity (20) (21) (22) (23) (24) (25) ; miR-221, miR-214, miR-128, miR-181, miR-33a and miR-27a were reported to induce osteosarcoma cell survival and promote cell proliferation (26) (27) (28) (29) (30) (31) .
It appears that miR-603 functions differentially in various types of tumors. Our results found that it acts as an oncogene by suppressing BRCC2. BRCC2 expression is reported to prevent apoptosis in a wide variety of cell types and as a target of miRNAs. Suppression or induction of BRCC2 affects tumorigenesis. miR-195, miR-24-2 and miR-365-2 were reported as negative regulators of BRCC2 through direct binding to their respective binding sites in the 3'-UTR of the human BRCC2 gene (32) . While, miR-15 and miR-16 induce apoptosis by targeting BRCC2 (33) .
The definition of osteosarcoma is deceptively straightforward. It is a malignant tumor of connective tissue origin within which tumor cells produce bone or osteoid (34) . Our results revealed that miR-603 enhanced tumor growth by downregulation of BRCC2 expression via translational inhibition in osteosarcoma cell lines and clinical samples. Increased miR-603 expression was associated with aggressive clinicopathological features and poor prognosis. The suppression of miR-603 exhibited an antitumor effect both in vitro and in vivo. Our findings demonstrate that miR-603 may be a potential novel target for the gene therapy of osteosarcoma.
In summary, the present study showed that miR-603 is significantly upregulated in osteosarcoma, meanwhile it is related with poor patient overall survival. This demonstrates that miR-603 has powerful oncogenic, proliferative and invasive regulatory effects that are mediated by BRCC2. The study indicates that miR-603 acts as an oncogene and is a promising therapeutic target in osteosarcoma.
